BAM
HZNP

Byrne Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Byrne Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27
Closed -$3K – 591
2023
Q3 		$3K Buy
+27
New +$2.9K ﹤0.01% 458
2023
Q2 		– Sell
-28
Closed -$3K – 651
2023
Q1 		$3K Buy
+28
New +$3.1K ﹤0.01% 535

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Byrne Asset Management's HZNP Position: Q4 2023 in Review

Byrne Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 27 shares — an estimated $3K sold.

Byrne Asset Management first reported a position in HZNP in Q1 2023 and held it in 2 quarters. The position peaked at $3K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Byrne Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Byrne Asset Management sold 27 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $3K.
  • Byrne Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 2 quarters.
  • Byrne Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Byrne Asset Management's 13F filing for Q4 2023, filed 29 Jan 2024.